Clinical trials are now underway throughout the United States to test the efficiency of new and powerful vaccines that are intended to prevent and treat the deadliest forms of cancer. The trials are due to the fast growth taking place in the field of medicine referred to as immunotherapy that some health officials say is the most promising solution to cancer that has yet to be seen.
Immunotherapy has exploded in popularity in recent years and is expected to soon become the focal point of the cancer industry which is worth $100 billion of the global economy. Both private investors and Big Pharma are optimistic regarding the state of the art treatment methods and are investing heavily in the many clinical trials taking place.
The American Cancer society names cancer as the second leading cause of death in the United States with more than 1.7 million cases of the disease predicted to be diagnosed for the year 2018. Additionally, more than 1600 people are expected to lose their lives to the disease daily and the total death tally for the year is expected to reach over 600,000.
Recent breakthroughs in drug research have afforded patients with treatments that have increased their chances of survival for the most part but industry experts explain that there is still much that is poorly understood regarding cancer treatment.
A present study taking place at Mount Sinai Hospital in New York City is focused on testing a recently developed vaccine that is intended to prevent the reoccurrence of deadly forms of cancer such as cancer in the lungs, breast, and bladder.
The team at Mount Sinai is led by Dr. Nina Bhardwaj and are performing a trial of a Personalized Genomic Vaccine that makes use of data regarding the genetic sequencing of tumors present in a patient to customize a vaccine. The vaccine design to attack specific targets that are identified as genetic mutations in the tumor.
The set of drugs being tested in the Mount Sinai study have not yet been approved by the Food and Drug Administration for mass production but researchers are hopeful that their findings will expedite the process.
Dr. Bhardwaj says that the current trials will center its attention on forms of cancer that have proven to have higher rates of mutation so that her research team can enjoy an increased opportunity to identify the stimuli that instigates an immune response.